Clindamycin-d<sub>3</sub> (hydrochloride)

Clindamycin-d3 (hydrochloride)

CAT N°: 35424
Price:

From 213.00 181.05

Clindamycin-d3 is intended for use as an internal standard for the quantification of clindamycin (Item Nos. 15006 | 35581) by GC- or LC-MS. Clindamycin is a lincosamide antibiotic.{60231,57596} It is active against Gram-positive bacteria, including various strains of S. pneumoniae, S. viridans, S. aureus, and S. epidermidis (MICs = 0.002-0.1, 0.005-0.2, 0.04-1.6, and 0.1-0.2 µg/ml, respectively).{60231} Clindamycin is also active against chloroquine-resistant and -sensitive strains of P. falciparum (IC50s = 3.12 and 8.81 nM, respectively).{57596} It inhibits bacterial protein synthesis by interacting with the 50S ribosome.{60231} Clindamycin increases survival in a mouse model of a secondary S. pneumoniae infection when administered at a dose of 15 mg/kg twice daily for seven days.{57597} Formulations containing clindamycin have been used in the treatment of bacterial infections.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (2S,4R)-N-((1S,2S)-2-chloro-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-1-(methyl-d3)-4-propylpyrrolidine-2-carboxamide, monohydrochloride
  • Correlated keywords
    • 1356992-88-5 U-21251 U21251 deuterated deuterium GCMS LCMS Streptococcus streptococci Staphylococcus Staphylococcus Plasmodium anti-biotic
  • Product Overview:
    Clindamycin-d3 is intended for use as an internal standard for the quantification of clindamycin (Item Nos. 15006 | 35581) by GC- or LC-MS. Clindamycin is a lincosamide antibiotic.{60231,57596} It is active against Gram-positive bacteria, including various strains of S. pneumoniae, S. viridans, S. aureus, and S. epidermidis (MICs = 0.002-0.1, 0.005-0.2, 0.04-1.6, and 0.1-0.2 µg/ml, respectively).{60231} Clindamycin is also active against chloroquine-resistant and -sensitive strains of P. falciparum (IC50s = 3.12 and 8.81 nM, respectively).{57596} It inhibits bacterial protein synthesis by interacting with the 50S ribosome.{60231} Clindamycin increases survival in a mouse model of a secondary S. pneumoniae infection when administered at a dose of 15 mg/kg twice daily for seven days.{57597} Formulations containing clindamycin have been used in the treatment of bacterial infections.

We also advise you